Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Rekart ML, Mun L, Aung A, Gomez D, Mulanda WK, et al.
2023-01-09 • Microbiology Spectrum
2023-01-09 • Microbiology Spectrum
We report the findings of a prospective laboratory diagnostic accuracy study to evaluate the sensitivity, specificity, and predictive values of the Xpert MTB/RIF Ultra assay for Mycobact...
Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M, et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...
Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A, et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Moreto-Planas L, Sagrado MJ, Mahajan R, Gallo J, Biague E, et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION Tuberculosis (TB) is an important cause of morbidity and mortality in children and over 50% of childhood TB remains undiagnosed every year. As microbiological confirmati...
